N-Carboxy-L-valine | 31147-07-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Carboxy-L-valine
• 英文别名: (2S)-2-(carboxyamino)-3-methylbutanoic acid
• CAS: 31147-07-6
• 化学式: C₆H₁₁NO₄
• 分子量: 161.16
• InChiKey: ULXFXLKKVOKWOZ-BYPYZUCNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  86.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010138368A1

  公开（公告）日：2010-12-02

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及在治疗HCV感染中使用这些化合物的方法。
• [EN] INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ PROTÉINE TYROSINE KINASE
  申请人：METHYLGENE INC

  公开号：WO2013044361A1

  公开（公告）日：2013-04-04

  The present invention provides new compounds and methods for treating a disease responsive to inhibition of kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity, for example a disease responsive to inhibition of protein tyrosine kinase activity of growth factor receptors, for example a disease responsive to inhibition of receptor type tyrosine kinase signaling, or for example, a disease responsive to inhibition of VEGF receptor signaling.

  本发明提供了用于治疗对激酶活性抑制敏感的疾病的新化合物和方法，例如对蛋白酪氨酸激酶活性抑制敏感的疾病，例如对生长因子受体蛋白酪氨酸激酶活性抑制敏感的疾病，例如对受体型酪氨酸激酶信号抑制敏感的疾病，或例如对VEGF受体信号抑制敏感的疾病。
• NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Buckman Brad

  公开号：US20110312996A1

  公开（公告）日：2011-12-22

  The embodiments provide compounds of the general Formulae VI, VII, VIII, IX, X, XI, XII, XIII, XIV, and XV as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供了通式VI、VII、VIII、IX、X、XI、XII、XIII、XIV和XV的化合物，以及包括药物组合物在内的组合物。本实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染和肝纤维化的方法，通常涉及向需要的个体施用所述化合物或组合物的有效量。
• [EN] 1,4(1,4)-DIPHENYLHEXACYCLOPHANE-12,43-DIYL DERIVATIVE, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] DÉRIVÉ 1,4(1,4)-DIPHÉNYLHEXACYCLOPHANE-12,43-DIYLE, PROCÉDÉ DE PRÉPARATION ET APPLICATION DE CELUI-CI<br/>[ZH] 1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用
  申请人：JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD

  公开号：WO2017076187A1

  公开（公告）日：2017-05-11

  提供一种1,4(1,4)-二苯杂环六蕃-12,43-二基衍生物及其制备方法与应用。该系列化合物可以抑制HCV的活性，可应用于治疗丙型肝炎病毒（HCV）感染相关疾病药物的开发，具有广阔的应用前景。见式（I）。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：GILEAD SCIENCES INC

  公开号：WO2012068234A2

  公开（公告）日：2012-05-24

  The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.